Guidelines for the management of inflammatory bowel disease in adults

Gut

Volumn 60, Issue 5, 2011, Pages 571-607

  Mowat, Craig ^a   Cole, Andrew ^b   Windsor, Al ^c   Ahmad, Tariq ^d   Arnott, Ian ^e   Driscoll, Richard ^f   Mitton, Sally ^g   Orchard, Tim ^h   Rutter, Matt ⁱ   Younge, Lisa ^j   Lees, Charlie ^e   Ho, Gwo Tzer ^e   Satsangi, Jack ^e   Bloom, Stuart ^c  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b ROYAL DERBY HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

^f Crohn's and Colitis UK Leeds and District Group   (United Kingdom)

^g ST GEORGE S HOSPITAL   (United Kingdom)

^h ST MARY S HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL OF NORTH TEES   (United Kingdom)

^j ROYAL LONDON HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BALSALAZIDE; CIPROFLOXACIN; CORTICOSTEROID; CYANOCOBALAMIN; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; DIVISTYRAMINE; FOLIC ACID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LENERCEPT; MERCAPTOPURINE; MESALAZINE; MESREN; METHOTREXATE; METRONIDAZOLE; OLSALAZINE; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; STEROID; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSCESS; ACNE; ADRENAL INSUFFICIENCY; ADULT; AGRANULOCYTOSIS; ANAPHYLAXIS; ARTHRALGIA; BACTERIAL INFECTION; CANCER RISK; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EXAMINATION; CLINICAL FEATURE; COLON BIOPSY; COLON RESECTION; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; CONSENSUS; CORTICOSTEROID INDUCED OSTEOPOROSIS; CROHN DISEASE; DEMYELINATING DISEASE; DIARRHEA; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; ECHOGRAPHY; EDEMA; ENTERIC FEEDING; ENTERITIS; EPIGASTRIC PAIN; FEMUR HEAD NECROSIS; FLUID INTAKE; FLUOROSCOPY; GINGIVA HYPERPLASIA; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HIRSUTISM; HISTOPATHOLOGY; HUMAN; ILEITIS; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE FISTULA; INTRACRANIAL PRESSURE; ISOTOPE LABELING; LEUKEMIA; LEUKOPENIA; LIVER FUNCTION TEST; LOW DRUG DOSE; LUNG ALVEOLITIS; LYMPHOMA; MACRONUTRIENT; MALAISE; MEDICAL DECISION MAKING; MEDICAL SOCIETY; METABOLIC BONE DISEASE; MOON FACE; MULTIPLE SCLEROSIS; MYALGIA; MYOPATHY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL SUPPORT; OLIGOSPERMIA; OPPORTUNISTIC INFECTION; PANCREATITIS; PARESTHESIA; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SAFETY; PERIPHERAL NEUROPATHY; PLASTIC SURGERY; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RECURRENT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN FISTULA; SMOKING CESSATION; SOLID TUMOR; STANDARDIZATION; STEVENS JOHNSON SYNDROME; STOMATITIS; SUBCAPSULAR CATARACT; TENDON DISEASE; TOTAL PARENTERAL NUTRITION; TREATMENT INDICATION; TREMOR; ULCERATIVE COLITIS; VOMITING;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DELIVERY OF HEALTH CARE; DIAGNOSTIC TECHNIQUES, DIGESTIVE SYSTEM; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; NUTRITIONAL SUPPORT; SMOKING CESSATION;

EID: 79953761841     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.224154     Document Type: Review

References (430)

1. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;(53 Suppl 5):V1-16.
2. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006;(55 Suppl 1):i1-15.
3. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;(55 Suppl 1):i16-35.
4. Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006;55:i36-58.
5. Biancone L, Michetti P, Travis S, et al. European evidence-based Consensus on the management of ulcerative colitis: special situations. J Crohns Colitis 2008;2:63-92. (Pubitemid 351179489)
6. Stange EF, Travis SPL, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008;2:1-23. (Pubitemid 351179487)
7. Travis SPL, Stange EF, Lemann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008;2:24-62. (Pubitemid 351179488)
8. UK IBD Audit 2006: National Results for the Organisation & Process of IBD Care in the UK. Royal College of Physicians of London, 2006.
9. Arnott Idr LK, Down C, Rhodes J, et al. Outcome of acute severe ulcerative colitis: data from the UK National IBD Audit. Gut 2009;58:A33.
10. Hayward RS, Wilson MC, Tunis SR, et al. Users' guides to the medical literature. VIII. How to use clinical practice guidelines. A. Are the recommendations valid? The Evidence-Based Medicine Working Group. JAMA 1995;274:570-4.
11. Quality Care Service Standards for the Healthcare of People who have Inflammatory Bowel Disease (ibd): Oyster Healthcare Communications Ltd, 2009.
12. Rubin GP, Hungin AP, Kelly PJ, et al. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000;14:1553-9. (Pubitemid 32011728)
13. Thomas GA, Millar-Jones D, Rhodes J, et al. Incidence of Crohn's disease in Cardiff over 60 years: 1986-1990 an update. Eur J Gastroenterol Hepatol 1995;7:401-5.
14. Logan RF. Inflammatory bowel disease incidence: up, down or unchanged? Gut 1998;42:309-11.
15. Armitage E, Drummond H, Ghosh S, et al. Incidence of juvenile-onset Crohn's disease in Scotland. Lancet 1999;353:1496-7. (Pubitemid 29204375)
16. Gunesh S, Thomas GA, Williams GT, et al. The incidence of Crohn's disease in Cardiff over the last 75 years: an update for 1996-2005. Aliment Pharmacol Ther 2008;27:211-19.
17. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-706.
18. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11. (Pubitemid 24195339)
19. Munkholm P, Langholz E, Davidsen M, et al. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993;105:1716-23. (Pubitemid 24002788)
20. Lennard-Jones JE, Shivananda S. Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur J Gastroenterol Hepatol 1997;9:353-9. (Pubitemid 27187332)
21. Winther KV, Jess T, Langholz E, et al. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 2003;125:1576-82. (Pubitemid 37500420)
22. Luces C, Bodger K. Economic burden of inflammatory bowel disease: a UK perspective. Expert Rev Pharmacoecon Outcomes Res 2006;6:471-82. (Pubitemid 44304755)
23. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;(19 Suppl A):5-36.
24. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-53. (Pubitemid 43764536)
25. Card T, Hubbard R, Logan RF. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 2003;125:1583-90. (Pubitemid 37500421)
26. Langholz E, Munkholm P, Davidsen M, et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992;103:1444-51.
27. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007;13:481-9. (Pubitemid 46668255)
28. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228-33. (Pubitemid 20366527)
29. Ekbom A, Helmick C, Zack M, et al. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990;336:357-9. (Pubitemid 20264156)
30. Friedman S, Rubin PH, Bodian C, et al. Screening and surveillance colonoscopy in chronic Crohn's colitis: results of a surveillance program spanning 25 years. Clin Gastroenterol Hepatol 2008;6:993-8; quiz 53-4.
31. Softley A, Clamp SE, Watkinson G, et al. The natural history of inflammatory bowel disease: has there been a change in the last 20 years? Scand J Gastroenterol Suppl 1988;144:20-3.
32. Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006;81:1462-71. (Pubitemid 44687433)
33. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004;126:1518-32. (Pubitemid 38649870)
34. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:1443-50. (Pubitemid 351813903)
35. Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1432-42.
36. Terheggen G, Lanyi B, Schanz S, et al. Safety, feasibility, and tolerability of ileocolonoscopy in inflammatory bowel disease. Endoscopy 2008;40:656-63.
37. Bourreille A, Ignjatovic A, Aabakken L, et al. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy 2009;41:618-37.
38. Jenkins D, Balsitis M, Gallivan S, et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. J Clin Pathol 1997;50:93-105. (Pubitemid 27093023)
39. Hyde GM, Jewell DP, Warren BF. Histological changes associated with the use of intravenous cyclosporin in the treatment of severe ulcerative colitis may mimic dysplasia. Colorectal Dis 2002;4:455-8. (Pubitemid 35331338)
40. Brenner DJ, Hall EJ. Computed tomography - an increasing source of radiation exposure. N Engl J Med 2007;357:2277-84. (Pubitemid 350190758)
41. Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. Br J Radiol 2008;81:362-78. (Pubitemid 351743850)
42. Parente F, Maconi G, Bollani S, et al. Bowel ultrasound in assessment of Crohn's disease and detection of related small bowel strictures: a prospective comparative study versus x ray and intraoperative findings. Gut 2002;50:490-5. (Pubitemid 34638867)
43. Dietrich CF. Significance of abdominal ultrasound in inflammatory bowel disease. Dig Dis 2009;27:482-93.
44. Gourtsoyiannis NC, Grammatikakis J, Papamastorakis G, et al. Imaging of small intestinal Crohn's disease: comparison between MR enteroclysis and conventional enteroclysis. Eur Radiol 2006;16:1915-25. (Pubitemid 44193176)
45. Albert JG, Martiny F, Krummenerl A, et al. Diagnosis of small bowel Crohn's disease: a prospective comparison of capsule endoscopy with magnetic resonance imaging and fluoroscopic enteroclysis. Gut 2005;54:1721-7. (Pubitemid 41697670)
46. Desmond AN, O'Regan K, Curran C, et al. Crohn's disease: factors associated with exposure to high levels of diagnostic radiation. Gut 2008;57:1524-9.
47. Stathaki MI, Koukouraki SI, Karkavitsas NS, et al. Role of scintigraphy in inflammatory bowel disease. World J Gastroenterol 2009;15:2693-700.
48. Sailer J, Peloschek P, Schober E, et al. Diagnostic value of CT enteroclysis compared with conventional enteroclysis in patients with Crohn's disease. AJR Am J Roentgenol 2005;185:1575-81.
49. Martin DR, Lauenstein T, Sitaraman SV. Utility of magnetic resonance imaging in small bowel Crohn's disease. Gastroenterology 2007;133:385-90. (Pubitemid 47187370)
50. Stratton RJ, Hackston A, Longmore D, et al. Malnutrition in hospital outpatients and inpatients: prevalence, concurrent validity and ease of use of the 'malnutrition universal screening tool' ('MUST') for adults. Br J Nutr 2004;92:799-808.
51. Headstrom PD, Rulyak SJ, Lee SD. Prevalence of and risk factors for vitamin B(12) deficiency in patients with Crohn's disease. Inflamm Bowel Dis 2008;14:217-23.
52. National Collaborating Centre for Acute Care. Nutrition Support in Adults Oral Nutrition Support, Enteral Tube Feeding and Parenteral Nutrition. London: National Collaborating Centre for Acute Care, 2006. http://www.rcseng.ac.uk.
53. Bakker H, Bozzetti F, Staun M, et al. Home parenteral nutrition in adults: a european multicentre survey in 1997. ESPEN-Home Artificial Nutrition Working Group. Clin Nutr 1999;18:135-40.
54. Nightingale J, Woodward JM. Guidelines for management of patients with a short bowel. Gut 2006;(55 Suppl 4):iv1-12.
55. Lochs H, Dejong C, Hammarqvist F, et al. ESPEN guidelines on enteral nutrition: gastroenterology. Clin Nutr 2006;25:260-74. (Pubitemid 43811680)
56. Fell JM, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000;14:281-9. (Pubitemid 30145315)
57. Sanderson IR, Udeen S, Davies PS, et al. Remission induced by an elemental diet in small bowel Crohn's disease. Arch Dis Child 1987;62:123-7. (Pubitemid 17004189)
58. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007;(1):CD000542.
59. Akobeng AK, Thomas AG. Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2007;(3):CD005984.
60. Heuschkel RB, Menache CC, Megerian JT, et al. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 2000;31:8-15. (Pubitemid 30456568)
61. Looijer-van Langen MA, Dieleman LA. Prebiotics in chronic intestinal inflammation. Inflamm Bowel Dis 2009;15:454-62.
62. Pham M, Lemberg DA, Day AS. Probiotics: sorting the evidence from the myths. Med J Aust 2008;188:304-8.
63. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-14. (Pubitemid 38083018)
64. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-9. (Pubitemid 36531796)
65. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539-46. (Pubitemid 41032360)
66. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009;104:437-43.
67. Schultz M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1012-18.
68. Rolfe VE, Fortun PJ, Hawkey CJ, et al. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006;(4):CD004826.
69. Van Gossum A, Cabre E, Hebuterne X, et al. ESPEN guidelines on parenteral nutrition: gastroenterology. Clin Nutr 2009;28:415-27.
70. Greenberg GR, Fleming CR, Jeejeebhoy KN, et al. Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. Gut 1988;29:1309-15.
71. McIntyre PB, Powell-Tuck J, Wood SR, et al. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 1986;27:481-5. (Pubitemid 16079746)
72. Payne-James JJ, Silk DB. Total parenteral nutrition as primary treatment in Crohn's diseasedRIP? Gut 1988;29:1304-8.
73. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989;34:1841-54. (Pubitemid 20018648)
74. Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 1996;110:424-31. (Pubitemid 26043875)
75. Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994;106:643-8. (Pubitemid 24064330)
76. Duffy LC, Zielezny MA, Marshall JR, et al. Cigarette smoking and risk of clinical relapse in patients with Crohn's disease. Am J Prev Med 1990;6:161-6. (Pubitemid 20282923)
77. Reese GE, Nanidis T, Borysiewicz C, et al. The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. Int J Colorectal Dis 2008;23:1213-21.
78. Sutherland LR, Ramcharan S, Bryant H, et al. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990;98:1123-8. (Pubitemid 20143093)
79. Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther 2005;21:921-31. (Pubitemid 40529727)
80. Kefalakes H, Stylianides TJ, Amanakis G, et al. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur J Clin Pharmacol 2009;65:963-70.
81. Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:196-202. (Pubitemid 43199690)
82. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003;17:29-42. (Pubitemid 36140432)
83. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;(2):CD000543.
84. Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2006;23:841-55.
85. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007;132:66-75; quiz 432-3.
86. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005;100:2478-85.
87. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005;54:960-5. (Pubitemid 40873909)
88. Kruis W, Kiudelis G, Racz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009;58:233-40.
89. Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010;(1):CD004115.
90. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;(2):CD000544.
91. Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:762-9.
92. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008;57:893-902. (Pubitemid 351919522)
93. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000;14:145-53.
94. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2:379-88. (Pubitemid 38561234)
95. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77:847-69. (Pubitemid 9242048)
96. Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol 1987;22:877-83. (Pubitemid 18041645)
97. Mahida YR, Jewell DP. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease. Digestion 1990;45:88-92. (Pubitemid 20151606)
98. Tremaine WJ, Schroeder KW, Harrison JM, et al. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994;19:278-82.
99. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993;104:1293-301. (Pubitemid 23235401)
100. Singleton J. Second trial of mesalamine therapy in the treatment of active Crohn's disease. Gastroenterology 1994;107:632-3. (Pubitemid 24233348)
101. Singleton JW, Hanauer S, Robinson M. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Dig Dis Sci 1995;40:931-5.
102. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst Rev 2005;(1):CD003715.
103. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004;19:179-89. (Pubitemid 38174887)
104. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002;51:536-9.
105. Van Staa TP, Travis S, Leufkens HG, et al. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology 2004;126:1733-9. (Pubitemid 38736338)
106. Muller AF, Stevens PE, McIntyre AS, et al. Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther 2005;21:1217-24. (Pubitemid 40733487)
107. Castiglione F, Rispo A, Di Girolamo E, et al. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment Pharmacol Ther 2003;18:1107-12. (Pubitemid 38021596)
108. Blichfeldt P, Blomhoff JP, Myhre E, et al. Metronidazole in Crohn's disease. A double blind cross-over clinical trial. Scand J Gastroenterol 1978;13:123-7. (Pubitemid 8269633)
109. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991;32:1071-5.
110. Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982;83:550-62.
111. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
112. Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009;15:17-24.
113. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994;39:1193-6. (Pubitemid 24190255)
114. Brandt LJ, Bernstein LH, Boley SJ, et al. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982;83:383-7. (Pubitemid 12078222)
115. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328-32. (Pubitemid 26067343)
116. Colombel JF, Lemann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999;94:674-8. (Pubitemid 29124865)
117. Mantzaris GJ, Archavlis E, Christoforidis P, et al. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 1997;92:454-6. (Pubitemid 27108180)
118. Turunen UM, Farkkila MA, Hakala K, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998;115:1072-8. (Pubitemid 28485596)
119. Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001;7:301-5. (Pubitemid 33062095)
120. Seow CH, Benchimol EI, Steinhart AH, et al. Budesonide for Crohn's disease. Expert Opin Drug Metab Toxicol 2009;5:971-9.
121. Campieri M, Adamo S, Valpiani D, et al. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther 2003;17:1471-80. (Pubitemid 36831438)
122. Manguso F, Balzano A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment Pharmacol Ther 2007;26:21-9.
123. Benchimol EI, Seow CH, Steinhart AH, et al. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008;(2):CD006792.
124. Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J 1962;2:1708-11.
125. Baron JH, Connell AM, Kanaghinis TG, et al. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962;2:441-3.
126. Lennard-Jones JE, Longmore AJ, Newell AC, et al. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut 1960;1:217-22.
127. Lofberg R, Danielsson A, Suhr O, et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996;110:1713-18. (Pubitemid 26169207)
128. Lee FI, Jewell DP, Mani V, et al. A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Gut 1996;38:229-33. (Pubitemid 26046818)
129. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997;40:775-81. (Pubitemid 27305471)
130. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66. (Pubitemid 14218578)
131. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811-18.
132. Kane SV, Schoenfeld P, Sandborn WJ, et al. The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther 2002;16:1509-17. (Pubitemid 34953592)
133. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-2.
134. Olaison G, Sjodahl R, Tagesson C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 1990;31:325-8. (Pubitemid 20093672)
135. Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis 2009;15:375-82.
136. Subramanian V, Saxena S, Kang JY, et al. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol 2008;103:2373-81.
137. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30.
138. Newby EA, Sawczenko A, Thomas AG, et al. Interventions for growth failure in childhood Crohn's disease. Cochrane Database Syst Rev 2005;(3):CD003873.
139. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:935-9. (Pubitemid 43374542)
140. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133-45. (Pubitemid 36519931)
141. McGovern DP, Travis SP, Duley J, et al. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 2002;122:838-9. (Pubitemid 34173838)
142. Bowen DG, Selby WS. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig Dis Sci 2000;45:1810-13.
143. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53. (Pubitemid 41820634)
144. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;(1):CD000478.
145. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2009;(4):CD000545.
146. Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009;(1):CD000067.
147. Gilissen LP, Bierau J, Derijks LJ, et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther 2005;22:605-11. (Pubitemid 41415988)
148. de Boer NK, Wong DR, Jharap B, et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 2007;102:2747-53. (Pubitemid 350179331)
149. Hande S, Wilson-Rich N, Bousvaros A, et al. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 2006;12:251-7.
150. Lennard L, Gibson BE, Nicole T, et al. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993;69:577-9. (Pubitemid 23355853)
151. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003;18:395-400. (Pubitemid 37070237)
152. Gisbert JP, Nino P, Rodrigo L, et al. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol 2006;101:2769-76. (Pubitemid 44902649)
153. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002;51:143-6. (Pubitemid 34791433)
154. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30. (Pubitemid 30346978)
155. Thomas CW Jr, Lowry PW, Franklin CL, et al. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis 2003;9:237-45.
156. Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 2008;103:1783-800.
157. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081-5. (Pubitemid 23245359)
158. Kinlen LJ, Sheil AG, Peto J, et al. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 1979;2:1461-6. (Pubitemid 10162309)
159. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005;54:617-22. (Pubitemid 40559243)
160. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121:1080-7. (Pubitemid 33022087)
161. Masunaga Y, Ohno K, Ogawa R, et al. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother 2007;41:21-8. (Pubitemid 46145952)
162. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5. (Pubitemid 41025906)
163. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25.
164. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000;118:1018-24. (Pubitemid 30346977)
165. Austin AS, Spiller RC. Inflammatory bowel disease, azathioprine and skin cancer: case report and literature review. Eur J Gastroenterol Hepatol 2001;13:193-4. (Pubitemid 32158215)
166. Subramanian V, Pollok RC, Kang JY, et al. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg 2006;93:793-9. (Pubitemid 44035250)
167. Myrelid P, Olaison G, Sjodahl R, et al. Thiopurine therapy is associated with postoperative intra-abdominal septic complications in abdominal surgery for Crohn's disease. Dis Colon Rectum 2009;52:1387-94.
168. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485-9. (Pubitemid 34638866)
169. Lemann M, Mary JY, Colombel JF, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005;128:1812-18. (Pubitemid 40824692)
170. Treton X, Bouhnik Y, Mary JY, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009;7:80-5.
171. Kim PS, Zlatanic J, Korelitz BI, et al. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Am J Gastroenterol 1999;94:3254-7.
172. Cassinotti A, Actis GC, Duca P, et al. Maintenance Treatment With Azathioprine in Ulcerative Colitis: Outcome and Predictive Factors After Drug Withdrawal. Am J Gastroenterol 2009;104:2760-7.
173. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2005;(1):CD003459.
174. Patel V, Macdonald JK, McDonald JW, et al. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009;(4):CD006884.
175. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-6. (Pubitemid 19073651)
176. Manosa M, Naves JE, Leal C, et al. Does methotrexate induce mucosal healing in Crohn's disease? Inflamm Bowel Dis 2010;16:377-8.
177. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7.
178. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32. (Pubitemid 30341531)
179. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416-21. (Pubitemid 26134073)
180. Ei-Matary W, Vandermeer B, Griffiths AM. Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2009;(3):CD007560.
181. Fraser AG, Morton D, McGovern D, et al. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:693-7. (Pubitemid 34407516)
182. Paoluzi OA, Pica R, Marcheggiano A, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002;16:1751-9.
183. Cummings JR, Herrlinger KR, Travis SP, et al. Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2005;21:385-9. (Pubitemid 40313940)
184. Wahed M, Louis-Auguste JR, Baxter LM, et al. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2009;30:614-20.
185. Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993;20:1845-9. (Pubitemid 24031585)
186. Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, doubleblind, controlled, phase IV trial. Arthritis Rheum 2008;58:73-81.
187. Din S, Dahele A, Fennel J, et al. Use of methotrexate in refractory Crohn's disease: the Edinburgh experience. Inflamm Bowel Dis 2008;14:756-62. (Pubitemid 351898059)
188. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther 2001;15:35-44. (Pubitemid 32055584)
189. Nathan DM, Iser JH, Gibson PR. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. J Gastroenterol Hepatol 2008;23:954-8. (Pubitemid 351806563)
190. Fraser AG. Methotrexate: first-line or second-line immunomodulator? Eur J Gastroenterol Hepatol 2003;15:225-31.
191. Te HS, Schiano TD, Kuan SF, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000;95:3150-6.
192. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006;131:283-311. (Pubitemid 44015759)
193. Hausmann J, Zabel K, Herrmann E, et al. Methotrexate for maintenance of remission in chronic active Crohn's disease: Long-term single-center experience and meta-analysis of observational studies. Inflamm Bowel Dis 2010;16:1195-202.
194. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-9. (Pubitemid 32322305)
195. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5. (Pubitemid 24188135)
196. Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005;(1):CD004277.
197. McDonald JW, Feagan BG, Jewell D, et al. Cyclosporine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2005;(2):CD000297.
198. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025-31. (Pubitemid 37193449)
199. Actis GC, Aimo G, Priolo G, et al. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis 1998;4:276-9. (Pubitemid 128699866)
200. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006;4:760-5. (Pubitemid 43833506)
201. Marion JF, Present D. 6-MP maintains cyclosporine-induced response in patients with severe acute colitis. Am J Gastroenterol 1996;91:1975.
202. Fernandez-Banares F, Bertran X, Esteve-Comas M, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996;91:2498-9. (Pubitemid 26406297)
203. Actis GC, Bresso F, Astegiano M, et al. Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis. Aliment Pharmacol Ther 2001;15:1307-11. (Pubitemid 32835536)
204. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a fiveyear experience. Am J Gastroenterol 1999;94:1587-92. (Pubitemid 29260450)
205. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255-62. (Pubitemid 44277355)
206. Herrlinger KR, Fellermann K, Stange EF. Tacrolimus - finally! Gut 2006;55:1224-5.
207. Yamamoto S, Nakase H, Mikami S, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008;28:589-97.
208. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002;8:317-24.
209. Bousvaros A, Kirschner BS, Werlin SL, et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000;137:794-9.
210. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. (Pubitemid 34621118)
211. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593-610. (Pubitemid 38649876)
212. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
213. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33.
214. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-38. (Pubitemid 351650483)
215. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65. (Pubitemid 46108762)
216. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9. (Pubitemid 47300424)
217. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405. (Pubitemid 29205403)
218. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85. (Pubitemid 38252535)
219. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;(3):CD005112.
220. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. (Pubitemid 41770166)
221. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250-60; quiz 520.
222. Afif W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009;15:1302-7.
223. Barreiro-de Acosta M, Lorenzo A, Dominguez-Munoz JE. Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years. World J Gastroenterol 2009;15:3814-16.
224. Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008;28:966-72.
225. Peyrin-Biroulet L, Laclotte C, Roblin X, et al. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007;13:2328-32. (Pubitemid 46860734)
226. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52:998-1002. (Pubitemid 36765292)
227. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11. (Pubitemid 40824691)
228. Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998;10:831-5. (Pubitemid 28493257)
229. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929-36. (Pubitemid 351451967)
230. Lees CW, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007;26:411-19. (Pubitemid 47063146)
231. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007;204:956-62; discussion 62-3.
232. Mor IJ, Vogel JD, da Luz Moreira A, et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 2008;51:1202-7; discussion 7-10.
233. Ferrante M, D'Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009;15:1062-70.
234. Yang Z, Wu Q, Wu K, Fan D. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther;31:486-92.
235. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
236. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5.
237. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008;27:19-30. (Pubitemid 350212629)
238. Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008;8:147-52.
239. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-5. (Pubitemid 39120128)
240. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8. (Pubitemid 36204954)
241. Bender NK, Heilig CE, Droll B, et al. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007;27:269-74. (Pubitemid 46088257)
242. West RL, Zelinkova Z, Wolbink GJ, et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008;28:1122-6.
243. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-54. (Pubitemid 44512213)
244. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49-54.
245. Rutgeerts P, Vermeire S, Van Assche G. Predicting the response to infliximab from trough serum levels. Gut 2010;59:7-8.
246. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)
247. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:501-8.
248. Russo EA, Harris AW, Campbell S, et al. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Aliment Pharmacol Ther 2009;29:308-14.
249. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31. (Pubitemid 38040720)
250. Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 2009;29:286-97.
251. Lees CW, Ironside J, Wallace WA, et al. Resolution of non-small-cell lung cancer after withdrawal of anti-TNF therapy. N Engl J Med 2008;359:320-1. (Pubitemid 352008468)
252. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:926-34. (Pubitemid 46684703)
253. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7. (Pubitemid 46175082)
254. Shale M, Kanfer E, Panaccione R, et al. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008;57:1639-41.
255. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-81.
256. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-65.
257. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7. (Pubitemid 351284485)
258. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
259. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008;134:1861-8. (Pubitemid 351790744)
260. Oussalah A, Chevaux JB, Fay R, et al. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol 2010;105:1142-9.
261. Ho GT, Mowat A, Potts L, et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther 2009;29:527-34.
262. Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009;36:635-41.
263. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041-8.
264. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9. (Pubitemid 18010466)
265. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974;4:627-30.
266. Cohen RD, Woseth DM, Thisted RA, et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95:1263-76. (Pubitemid 30263523)
267. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92:1867-71. (Pubitemid 27440908)
268. Hanauer SB. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflamm Bowel Dis 1998;4:79-83.
269. Allison MC, Vallance R. Prevalence of proximal faecal stasis in active ulcerative colitis. Gut 1991;32:179-82.
270. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10. (Pubitemid 26231777)
271. Rosenberg W, Ireland A, Jewell DP. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol 1990;12:40-1. (Pubitemid 20056512)
272. Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007;5:103-10. (Pubitemid 46096828)
273. Gonzalez-Huix F, Fernandez-Banares F, Esteve-Comas M, et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 1993;88:227-32. (Pubitemid 23053475)
274. Kishore J, Ghoshal U, Ghoshal UC, et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol 2004;53:1155-60. (Pubitemid 40052501)
275. Minami M, Ohta M, Ohkura T, et al. Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan. World J Gastroenterol 2007;13:754-60.
276. Papadakis KA, Tung JK, Binder SW, et al. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol 2001;96:2137-42. (Pubitemid 32660910)
277. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidenced based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3:47-91.
278. Irving PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol 2005;3:617-28. (Pubitemid 40984719)
279. Bojic D, Radojicic Z, Nedeljkovic-Protic M, et al. Long-term outcome after admission for acute severe ulcerative colitis in Oxford: the 1992-1993 cohort. Inflamm Bowel Dis 2009;15:823-8.
280. Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000;(2): CD000952.
281. Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007;132:507-15.
282. Alves A, Panis Y, Bouhnik Y, et al. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg 2003;197:379-85. (Pubitemid 38373296)
283. Brown SR, Haboubi N, Hampton J, et al. The management of acute severe colitis: ACPGBI position statement. Colorectal Dis 2008;(10 Suppl 3):8-29.
284. Seidel SA, Newman M, Sharp KW. Ileoanal pouch versus ileostomy: is there a difference in quality of life? Am Surg 2000;66:540-6; discussion 546-7.
285. Singh B, Mortensen N, Shorthouse AJ. Defunctioning ileostomy following restorative proctocolectomy. Ann R Coll Surg Engl 2008;90:541-5.
286. Heuschen UA, Hinz U, Allemeyer EH, et al. One- or two-stage procedure for restorative proctocolectomy: rationale for a surgical strategy in ulcerative colitis. Ann Surg 2001;234:788-94. (Pubitemid 33117199)
287. Remzi FH, Fazio VW, Gorgun E, et al. The outcome after restorative proctocolectomy with or without defunctioning ileostomy. Dis Colon Rectum 2006;49:470-7.
288. Keighley MR, Yoshioka K, Kmiot W. Prospective randomized trial to compare the stapled double lumen pouch and the sutured quadruple pouch for restorative proctocolectomy. Br J Surg 1988;75:1008-11. (Pubitemid 19009400)
289. Lovegrove RE, Constantinides VA, Heriot AG, et al. A comparison of hand-sewn versus stapled ileal pouch anal anastomosis (IPAA) following proctocolectomy: a meta-analysis of 4183 patients. Ann Surg 2006;244:18-26. (Pubitemid 44297444)
290. Berndtsson I, Oresland T. Quality of life before and after proctocolectomy and IPAA in patients with ulcerative proctocolitis - a prospective study. Colorectal Dis 2003;5:173-9. (Pubitemid 36452280)
291. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg 1995;222:120-7.
292. Heuschen UA, Hinz U, Allemeyer EH, et al. Risk factors for ileoanal J pouch-related septic complications in ulcerative colitis and familial adenomatous polyposis. Ann Surg 2002;235:207-16.
293. Delaini GG, Scaglia M, Colucci G, et al. The ileoanal pouch procedure in the long-term perspective: a critical review. Tech Coloproctol 2005;9:187-92. (Pubitemid 41772329)
294. Fazio VW, Tekkis PP, Remzi F, et al. Quantification of risk for pouch failure after ileal pouch anal anastomosis surgery. Ann Surg 2003;238:605-14; discussion 614-17.
295. Fazio VW, O'Riordain MG, Lavery IC, et al. Long-term functional outcome and quality of life after stapled restorative proctocolectomy. Ann Surg 1999;230:575-84; discussion 584-6.
296. Tulchinsky H, Hawley PR, Nicholls J. Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg 2003;238:229-34. (Pubitemid 38174497)
297. Tekkis PP, Senagore AJ, Delaney CP, et al. Evaluation of the learning curve in laparoscopic colorectal surgery: comparison of right-sided and left-sided resections. Ann Surg 2005;242:83-91. (Pubitemid 40917971)
298. Kaplan GG, McCarthy EP, Ayanian JZ, et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 2008;134:680-7.
299. Raval MJ, Schnitzler M, O'Connor BI, et al. Improved outcome due to increased experience and individualized management of leaks after ileal pouch-anal anastomosis. Ann Surg 2007;246:763-70. (Pubitemid 350035652)
300. Hyman NH, Cataldo P, Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease. Dis Colon Rectum 2005;48:70-3. (Pubitemid 40895658)
301. Aberra FN, Lewis JD, Hass D, et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003;125:320-7. (Pubitemid 36929411)
302. Poritz LS, Rowe WA, Swenson BR, et al. Intravenous cyclosporine for the treatment of severe steroid refractory ulcerative colitis: what is the cost? Dis Colon Rectum 2005;48:1685-90.
303. Ferrante M, Declerck S, De Hertogh G, et al. Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflamm Bowel Dis 2008;14:20-8. (Pubitemid 351196864)
304. Michelassi F, Lee J, Rubin M, et al. Long-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study. Ann Surg 2003;238:433-41; discussion 442-5.
305. Tekkis PP, Lovegrove RE, Tilney HS, et al. Long-term failure and function after restorative proctocolectomyda multi-centre study of patients from the uk national ileal pouch registry. Colorectal Dis 2010;12:433-41.
306. Johnson P, Richard C, Ravid A, et al. Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum 2004;47:1119-26. (Pubitemid 38857058)
307. Gorgun E, Remzi FH, Goldberg JM, et al. Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients. Surgery 2004;136:795-803. (Pubitemid 39311305)
308. Ording Olsen K, Juul S, Berndtsson I, et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 2002;122:15-19. (Pubitemid 34049189)
309. Sagar PM, Pemberton JH. Ileo-anal pouch function and dysfunction. Dig Dis 1997;15:172-88. (Pubitemid 127523167)
310. Shen B, Achkar JP, Lashner BA, et al. Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology 2001;121:261-7. (Pubitemid 32729373)
311. Bell AJ, Price AB, Forbes A, et al. Pre-pouch ileitis: a disease of the ileum in ulcerative colitis after restorative proctocolectomy. Colorectal Dis 2006;8:402-10. (Pubitemid 43676655)
312. Shen B, Achkar JP, Lashner BA, et al. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. Am J Gastroenterol 2002;97:972-7. (Pubitemid 34408256)
313. Shen B, Lashner BA, Bennett AE, et al. Treatment of rectal cuff inflammation (cuffitis) in patients with ulcerative colitis following restorative proctocolectomy and ileal pouch-anal anastomosis. Am J Gastroenterol 2004;99:1527-31. (Pubitemid 39180102)
314. Gionchetti P, Rizzello F, Morselli C, et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007;50:2075-82; discussion 2082-4.
315. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-9. (Pubitemid 30621980)
316. Mimura T, Rizzello F, Helwig U, et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002;16:909-17. (Pubitemid 34461760)
317. Sandborn WJ, McLeod R, Jewell DP. Medical therapy for induction and maintenance of remission in pouchitis: a systematic review. Inflamm Bowel Dis 1999;5:33-9.
318. Gionchetti P, Rizzello F, Poggioli G, et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther 2007;25:1231-6. (Pubitemid 46650294)
319. Sambuelli A, Boerr L, Negreira S, et al. Budesonide enema in pouchitisea double-blind, double-dummy, controlled trial. Aliment Pharmacol Ther 2002;16:27-34. (Pubitemid 34123861)
320. Winter TA, Dalton HR, Merrett MN, et al. Cyclosporin A retention enemas in refractory distal ulcerative colitis and 'pouchitis'. Scand J Gastroenterol 1993;28:701-4. (Pubitemid 23231991)
321. de Silva HJ, Ireland A, Kettlewell M, et al. Short-chain fatty acid irrigation in severe pouchitis. N Engl J Med 1989;321:1416-17. (Pubitemid 19284215)
322. Ferrante M, D'Haens G, Dewit O, et al. Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: A Belgian case series. Inflamm Bowel Dis 2010;16:243-9.
323. Holubar SD, Cima RR, Sandborn WJ, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2010;(6):CD001176.
324. Alves A, Panis Y, Bouhnik Y, et al. Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn's disease: a multivariate analysis in 161 consecutive patients. Dis Colon Rectum 2007;50:331-6. (Pubitemid 46393968)
325. Hulten L. Surgical treatment of Crohn's disease of the small bowel or ileocecum. World J Surg 1988;12:180-5.
326. McGovern DP, Travis SP. Thiopurine therapy: when to start and when to stop. Eur J Gastroenterol Hepatol 2003;15:219-23. (Pubitemid 36337839)
327. Clare DF, Alexander FC, Mike S, et al. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2009;21:71-5.
328. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875-80. (Pubitemid 34267269)
329. Hellers G, Bergstrand O, Ewerth S, et al. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut 1980;21:525-7. (Pubitemid 10059414)
330. Buchmann P, Keighley MR, Allan RN, et al. Natural history of perianal Crohn's disease. Ten year follow-up: a plea for conservatism. Am J Surg 1980;140:642-4. (Pubitemid 11240766)
331. Rutgeerts P. Review article: treatment of perianal fistulizing Crohn's disease. Aliment Pharmacol Ther 2004;(20 Suppl 4):106-10. (Pubitemid 39319258)
332. Nordgren S, Fasth S, Hulten L. Anal fistulas in Crohn's disease: incidence and outcome of surgical treatment. Int J Colorectal Dis 1992;7:214-18. (Pubitemid 23014436)
333. Sandborn WJ, Fazio VW, Feagan BG, et al. AGA technical review on perianal Crohn's disease. Gastroenterology 2003;125:1508-30. (Pubitemid 37409772)
334. Vermeire S, Van Assche G, Rutgeerts P. Perianal Crohn's disease: classification and clinical evaluation. Dig Liver Dis 2007;39:959-62. (Pubitemid 47354984)
335. Gaertner WB, Decanini A, Mellgren A, et al. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? Dis Colon Rectum 2007;50:1754-60.
336. Ardizzone S, Maconi G, Colombo E, et al. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis 2004;10:91-6. (Pubitemid 38332167)
337. Bell SJ, Halligan S, Windsor AC, et al. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2003;17:387-93. (Pubitemid 36259401)
338. Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980;79:357-65. (Pubitemid 10046383)
339. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128:862-9. (Pubitemid 40523539)
340. Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004;2:912-20. (Pubitemid 39335798)
341. American Gastroenterological Association medical position statement: perianal Crohn's disease. Gastroenterology 2003;125:1503-7.
342. Talbot C, Sagar PM, Johnston MJ, et al. Infliximab in the surgical management of complex fistulating anal Crohn's disease. Colorectal Dis 2005;7:164-8.
343. Topstad DR, Panaccione R, Heine JA, et al. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum 2003;46:577-83. (Pubitemid 36576412)
344. O'Connor L, Champagne BJ, Ferguson MA, et al. Efficacy of anal fistula plug in closure of Crohn's anorectal fistulas. Dis Colon Rectum 2006;49:1569-73. (Pubitemid 44796128)
345. Jess T, Winther KV, Munkholm P, et al. Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology 2002;122:1808-14. (Pubitemid 34651425)
346. Kwan LY, Conklin JL, Papadakis KA. Esophageal Crohn's disease treated successfully with adalimumab. Inflamm Bowel Dis 2007;13:639-40. (Pubitemid 46799648)
347. Hassan C, Zullo A, De Francesco V, et al. Systematic review: Endoscopic dilatation in Crohn's disease. Aliment Pharmacol Ther 2007;26:1457-64. (Pubitemid 350178804)
348. East JE, Brooker JC, Rutter MD, et al. A pilot study of intrastricture steroid versus placebo injection after balloon dilatation of Crohn's strictures. Clin Gastroenterol Hepatol 2007;5:1065-9.
349. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000;231:38-45. (Pubitemid 30043937)
350. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005;54:237-41. (Pubitemid 40139240)
351. Vermeire S, van Assche G, Rutgeerts P. Review article: Altering the natural history of Crohn's disease - evidence for and against current therapies. Aliment Pharmacol Ther 2007;25:3-12. (Pubitemid 44902859)
352. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956-63. (Pubitemid 20338451)
353. Kim NK, Senagore AJ, Luchtefeld MA, et al. Long-term outcome after ileocecal resection for Crohn's disease. Am Surg 1997;63:627-33. (Pubitemid 27268587)
354. Nordgren SR, Fasth SB, Oresland TO, et al. Long-term follow-up in Crohn's disease. Mortality, morbidity, and functional status. Scand J Gastroenterol 1994;29:1122-8. (Pubitemid 24374804)
355. Marchal L, D'Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 2004;19:749-54. (Pubitemid 38496640)
356. Young-Fadok TM, HallLong K, McConnell EJ, et al. Advantages of laparoscopic resection for ileocolic Crohn's disease. Improved outcomes and reduced costs. Surg Endosc 2001;15:450-4.
357. Tan JJ, Tjandra JJ. Laparoscopic surgery for Crohn's disease: a meta-analysis. Dis Colon Rectum 2007;50:576-85. (Pubitemid 46870468)
358. Eshuis EJ, Polle SW, Slors JF, et al. Long-term surgical recurrence, morbidity, quality of life, and body image of laparoscopic-assisted vs. open ileocolic resection for Crohn's disease: a comparative study. Dis Colon Rectum 2008;51:858-67.
359. Lawes DA, Motson RW. Avoidance of laparotomy for recurrent disease is a long-term benefit of laparoscopic resection for Crohn's disease. Br J Surg 2006;93:607-8.
360. Stocchi L, Milsom JW, Fazio VW. Long-term outcomes of laparoscopic versus open ileocolic resection for Crohn's disease: follow-up of a prospective randomized trial. Surgery 2008;144:622-7; discussion 627-8.
361. Polle SW, Slors JF, Weverling GJ, et al. Recurrence after segmental resection for colonic Crohn's disease. Br J Surg 2005;92:1143-9. (Pubitemid 41284880)
362. Tekkis PP, Purkayastha S, Lanitis S, et al. A comparison of segmental vs subtotal/total colectomy for colonic Crohn's disease: a meta-analysis. Colorectal Dis 2006;8:82-90. (Pubitemid 43372454)
363. Fichera A, McCormack R, Rubin MA, et al. Long-term outcome of surgically treated Crohn's colitis: a prospective study. Dis Colon Rectum 2005;48:963-9. (Pubitemid 40884185)
364. Fearnhead NS, Chowdhury R, Box B, et al. Long-term follow-up of strictureplasty for Crohn's disease. Br J Surg 2006;93:475-82.
365. Michelassi F, Upadhyay GA. Side-to-side isoperistaltic strictureplasty in the treatment of extensive Crohn's disease. J Surg Res 2004;117:71-8. (Pubitemid 38317212)
366. Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn's disease: a systematic review and meta-analysis. Dis Colon Rectum 2007;50:1968-86. (Pubitemid 350077088)
367. Heuman R, Boeryd B, Bolin T, et al. The influence of disease at the margin of resection on the outcome of Crohn's disease. Br J Surg 1983;70:519-21. (Pubitemid 13001790)
368. Becker JM. Surgical therapy for ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1999;28:371-90, viiieix.
369. Onali S, Petruzziello C, Calabrese E, et al. Frequency, pattern, and risk factors of postoperative recurrence of Crohn's disease after resection different from ileo-colonic. J Gastrointest Surg 2009;13:246-52.
370. Ikeuchi H, Kusunoki M, Yamamura T. Long-term results of stapled and hand-sewn anastomoses in patients with Crohn's disease. Dig Surg 2000;17:493-6. (Pubitemid 32008800)
371. Munoz-Juarez M, Yamamoto T, Wolff BG, et al. Wide-lumen stapled anastomosis vs. conventional end-to-end anastomosis in the treatment of Crohn's disease. Dis Colon Rectum 2001;44:20-5; discussion 25-6.
372. Simillis C, Purkayastha S, Yamamoto T, et al. A meta-analysis comparing conventional end-to-end anastomosis vs. other anastomotic configurations after resection in Crohn's disease. Dis Colon Rectum 2007;50:1674-87. (Pubitemid 47583357)
373. McLeod RS, Wolff BG, Ross S, et al. Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. Dis Colon Rectum 2009;52:919-27.
374. Blum E, Katz JA. Postoperative therapy for Crohn's disease. Inflamm Bowel Dis 2009;15:463-72.
375. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004;127:723-9. (Pubitemid 39208405)
376. Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004;127:730-40. (Pubitemid 39208406)
377. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009;104:2089-96.
378. Duerksen DR, Fallows G, Bernstein CN. Vitamin B12 malabsorption in patients with limited ileal resection. Nutrition 2006;22:1210-13. (Pubitemid 44692455)
379. Behrend C, Jeppesen PB, Mortensen PB. Vitamin B12 absorption after ileorectal anastomosis for Crohn's disease: effect of ileal resection and time span after surgery. Eur J Gastroenterol Hepatol 1995;7:397-400.
380. Suchy FS, Balistreri WF. Ileal dysfunction in Crohn's disease assessed by the postprandial serum bile acid response. Gut 1981;22:948-52. (Pubitemid 12193612)
381. Farkkila MA, Kairemo KJ, Taavitsainen MJ, et al. Plasma lathosterol as a screening test for bile acid malabsorption due to ileal resection: correlation with 75SeHCAT test and faecal bile acid excretion. Clin Sci (Lond) 1996;90:315-19.
382. Brydon WG, Nyhlin H, Eastwood MA, et al. Serum 7 alpha-hydroxy-4- cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. Eur J Gastroenterol Hepatol 1996;8:117-23. (Pubitemid 26130232)
383. Minderhoud IM, Oldenburg B, van Dam PS, et al. High prevalence of fatigue in quiescent inflammatory bowel disease is not related to adrenocortical insufficiency. Am J Gastroenterol 2003;98:1088-93. (Pubitemid 36733771)
384. Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002;(51 Suppl 5):V10-12.
385. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a metaanalysis. Gastrointest Endosc 2002;56:48-54. (Pubitemid 41115048)
386. Ullman T, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003;125:1311-19. (Pubitemid 37409751)
387. Collins PD, Mpofu C, Watson AJ, et al. Strategies for detecting colon cancer and/ or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006;(2):CD000279.
388. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010;59:666-89.
389. Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007;56:830-7. (Pubitemid 46854200)
390. Bar-Oz B, Bulkowstein M, Benyamini L, et al. Use of antibiotic and analgesic drugs during lactation. Drug Saf 2003;26:925-35. (Pubitemid 37330555)
391. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000;62:385-92.
392. Norgard B, Hundborg HH, Jacobsen BA, et al. Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol 2007;102:1947-54. (Pubitemid 47301527)
393. Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis;16:881-95.
394. Branche J, Cortot A, Bourreille A, et al. Cyclosporine treatment of steroidrefractory ulcerative colitis during pregnancy. Inflamm Bowel Dis 2009;15:1044-8.
395. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004;99:2385-92. (Pubitemid 40039370)
396. Mahadevan U. Gastrointestinal medications in pregnancy. Best Pract Res Clin Gastroenterol 2007;21:849-77. (Pubitemid 47413173)
397. Kane S, Ford J, Cohen R, et al. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol 2009;43:613-16.
398. Williams H, Walker D, Orchard TR. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 2008;10:597-605.
399. LaRusso NF, Shneider BL, Black D, et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006;44:746-64. (Pubitemid 44433732)
400. Mendes FD, Levy C, Enders FB, et al. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol 2007;102:344-50. (Pubitemid 46160549)
401. Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002;(51 Suppl 6):VI1-9.
402. Jess T, Loftus EV Jr, Velayos FS, et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 2007;102:829-36. (Pubitemid 46496613)
403. Broome U, Lofberg R, Veress B, et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995;22:1404-8.
404. Cullen SN, Rust C, Fleming K, et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008;48:792-800.
405. Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-14.
406. Chapman RW. Primary sclerosing cholangitis: what is the role of ursodeoxycholic acid in therapy for PSC? Nat Rev Gastroenterol Hepatol 2010;7:74-5.
407. Pardi DS, Loftus EV Jr, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-93. (Pubitemid 36389790)
408. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95. (Pubitemid 32096335)
409. Gasche C, Lomer MC, Cavill I, et al. Iron, anaemia, and inflammatory bowel diseases. Gut 2004;53:1190-7. (Pubitemid 38961976)
410. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007;13:1545-53.
411. Bermejo F, Garcia-Lopez S. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J Gastroenterol 2009;15:4638-43.
412. Vijverman A, Piront P, Belaiche J, et al. Evolution of the prevalence and characteristics of anemia in inflammatory bowel diseases between 1993 and 2003. Acta Gastroenterol Belg 2006;69:1-4.
413. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008;103:1182-92. (Pubitemid 351677967)
414. Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005;40:1058-65. (Pubitemid 41291355)
415. Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease - a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005;100:2503-9.
416. Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 1996;334:619-23. (Pubitemid 26076567)
417. Rahier JF, Yazdanpanah Y, Colombel JF, et al. The European (ECCO) Consensus on infection in IBD: what does it change for the clinician? Gut 2009;58:1313-15.
418. Salisbury D, Ramsay M, Noakes K. Immunisation Against Infectious Disease. Joint Committee on Vaccination and Immunisation, Great Britain Dept. of Health London: Stationery Office, Dept of Health, London, 2006.
419. Walker JR, Ediger JP, Graff LA, et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol 2008;103:1989-97.
420. Fuller-Thomson E, Sulman J. Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflamm Bowel Dis 2006;12:697-707. (Pubitemid 44253753)
421. Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis 2009;15:1105-18.
422. Graff LA, Walker JR, Clara I, et al. Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. Am J Gastroenterol 2009;104:2959-69.
423. Santos J, Alonso C, Vicario M, et al. Neuropharmacology of stress-induced mucosal inflammation: implications for inflammatory bowel disease and irritable bowel syndrome. Curr Mol Med 2008;8:258-73. (Pubitemid 351982530)
424. Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut 2005;54:1481-91. (Pubitemid 41375207)
425. Maunder RG, Levenstein S. The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence. Curr Mol Med 2008;8:247-52. (Pubitemid 351982528)
426. Bitton A, Dobkin PL, Edwardes MD, et al. Predicting relapse in Crohn's disease: a biopsychosocial model. Gut 2008;57:1386-92.
427. von Wietersheim J, Kessler H. Psychotherapy with chronic inflammatory bowel disease patients: a review. Inflamm Bowel Dis 2006;12:1175-84.
428. Mikocka-Walus AA, Turnbull DA, Moulding NT, et al. Antidepressants and inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Ment Health 2006;2:24.
429. Blum RW, Garell D, Hodgman CH, et al. Transition from child-centered to adult health-care systems for adolescents with chronic conditions. A position paper of the Society for Adolescent Medicine. J Adolesc Health 1993;14:570-6. (Pubitemid 23345069)
430. Viner R. Transition from paediatric to adult care. Bridging the gaps or passing the buck? Arch Dis Child 1999;81:271-5.